Open an account

Anavex Life Sciences

AVXL · NASDAQ

$1.36+$0.11 (+8.80%)TodayMarket closed ·
Prev close $1.25

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.

Employees
34
Headquarters
New York City, New York
Listed
Apr 13, 2006
Sector
Health Care
Industry
Biotechnology
Website
anavex.com

AVXL key statistics

Market cap
126.07M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.45M
Volume
1.67M
Open price
$1.25
High today
$1.40
Low today
$1.23
52 Week high
$9.50
52 Week low
$1.14

Anavex Life Sciences (AVXL) at a glance

Anavex Life Sciences (AVXL) last traded at $1.36, with a market cap of 126.07M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.23 and $1.40. The current price is 11.0% above the day's low and 2.9% below its high.

Volume so far is 1.67M shares, in line with the average of 1.45M shares a day.

Over the past year Anavex Life Sciences has ranged from $1.14 to $9.50, and now sits 3% of the way up that range.

Anavex Life Sciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY26 it reported -$0.08 per share against an estimate of -$0.0816.

The average analyst price target is $20.40, 1400.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 3 analystsAvg $20.40
Low
$20.20
Now
$1.36
High
$21.00

AVXL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 20.4% on average.

  1. Q4 FY24: reported -$0.14 per share against an estimate of -$0.1666
  2. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1734
  3. Q2 FY25: reported -$0.13 per share against an estimate of -$0.153
  4. Q3 FY25: reported -$0.16 per share against an estimate of -$0.1462
  5. Q4 FY25: reported -$0.11 per share against an estimate of -$0.153
  6. Q1 FY26: reported -$0.06 per share against an estimate of -$0.1122
  7. Q2 FY26: reported -$0.06 per share against an estimate of -$0.0714
  8. Q3 FY26: reported -$0.08 per share against an estimate of -$0.0816

AVXL news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL

  • Press releaseGlobe Newswire

    Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

  • Press releaseNewsfile

    Kaplan Fox Reminds Anavex Life Sciences Corp. (AVXL) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 30, 2026

  • Press releaseNewsfile

    Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL

  • Press releaseNewsfile

    Kaplan Fox Encourages Anavex Life Sciences Corp. (AVXL) Investors to Contact the Firm Before the Deadline on November 30, 2026 for a Leadership Role

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL

  • Press releaseBusiness Wire

    AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights

  • Press releaseNewsfile

    Kaplan Fox Advises Anavex Life Sciences Corp. (AVXL) Investors to Act Before the Lead Plaintiff Deadline on November 30, 2026

Similar companies

Companies in the same industry as Anavex Life Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.